Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111020
Status:
COMPLETED
Last Update Posted:
2014-08-06
First Post:
2005-05-16
Brief Title:
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Open Label Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib BAY43-9006 which is being studied in clinical trials for kidney cancer and other kinds of cancer This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment All patients in this protocol will be treated with sorafenib In addition data from the patients who participate in this protocol will provide additional information about the drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None